← boardnext 2026-10
OGN
Organon and Codistress 2/10 · well-funded / low risk$13.54+0%today0% from 52w high
Lead: Atopic Dermatitis · est. market ~$15B (approx, global)
Revenue
$1460M
Liquidity
$1116M
Runway
—
Shares 1y
+1%
Price & events
+39.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+0.3%
1W
+0.6%
1M
+57.6%
3M
+39.2%
6M
+35.2%
1Y
-33.0%
2Y
-44.3%
5Y
-50.1%
All
Overview
- Market Cap
- $3.55B
- Enterprise Value
- $10.99B
- Volume
- 62.59K
- 52 Week Range
- $5.70 – $13.56
- Total Shares
- 262.60M
- Float Shares
- 261.08M
- Short %
- 7.40%
- % Held by Insiders
- 0.47%
- % Held by Institutions
- 77.78%
- RVOL
- 0.03x
- Beta
- 1.54
Pipeline stages · 1 programs
Tapinarof cream, 1%, Vehicle Cream
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | tapinarof cream, 1% | Plaque Psoriasis | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 3 | Tapinarof cream, 1%, Vehicle Cream | Atopic Dermatitis | — | recruiting |
Catalyst news & presentations · 4
- 2026-08-04earningsEarningsEarnings releaseyahoo
- 2026-04-26partnershipEntry into definitive merger agreement with Sun Pharma to be acquired for $14.00 per share cash.SEC 8-K
- March 12, 2025PDUFAPDUFAVTAMA (tapinarof) · New target action date for FDA review of sNDA for VTAMA cream in atopic dermatitis.SEC 8-K
- 2024-11-05pdufa extensionVTAMA (tapinarof) · FDA extended review by three months, new PDUFA date March 12, 2025.SEC 8-K
Approved drugs (14)
- VTAMATAPINAROF2022 · Prescription
- XACIATOCLINDAMYCIN PHOSPHATE2021 · Prescription
- ASMANEX HFAMOMETASONE FUROATE2014 · Prescription
- LIPTRUZETATORVASTATIN CALCIUM2013 · Discontinued
- DULERAFORMOTEROL FUMARATE2010 · Prescription
- IMPLANONETONOGESTREL2006 · Discontinued
- CLARINEX-D 12 HOURDESLORATADINE2006 · Prescription
- FOLLISTIM AQFOLLITROPIN ALFA/BETA2005 · Discontinued
- FOSAMAX PLUS DALENDRONATE SODIUM2005 · Prescription
- ASMANEX TWISTHALERMOMETASONE FUROATE2005 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $11 (-17% upside) · 4 analysts
- 2026-04-29BNP ParibasOutperform → Neutral
- 2026-04-28Piper SandlerUnderweight → Neutral
- 2026-02-24BarclaysUnderweight
- 2025-12-09BarclaysUnderweight
- 2025-11-11JP MorganUnderweight
- 2025-11-11Morgan StanleyEqual-Weight
Competitors — Atopic Dermatitis
- ABBVAbbVie Inc.$451.1B · D2
- PFEPFIZER INC$142.2B · D3
- ROIVRoivant Sciences Ltd.$25.1B · D0
- KYMRKymera Therapeutics, Inc.$9.1B · D5
- NKTRNEKTAR THERAPEUTICS$2.3B · D8
- CRVSCorvus Pharmaceuticals, Inc.$1.1B · D4
- ACRSAclaris Therapeutics, Inc.$769M · D4
- EVMNEvommune, Inc.$405M · D3
- TTRXTurn Therapeutics Inc.$287M · D2
- APGEApogee Therapeutics, Inc.— · D2
Recent news
- 2026-07-22Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
- 2026-07-21Organon & Co. (OGN) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Organon & Co. (OGN) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-17[8-K] Organon & Co. Reports Material Event - Stock Titan
- 2026-07-15Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
- 2026-07-14Organon & Co.: Great Odds, Small Prize, Big Penalty (NYSE:OGN) - Seeking Alpha
- 2026-07-09Organon (OGN) Q1 2026 earnings summary - Quartr
- 2026-07-08Organon (OGN) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.